title: A prospective comparison of wedge matrix resection with nail matrix phenolization for the treatment of ingrown toenail.
abstract: In a prospective study, 110 patients with ingrown toenails were operated on, 55 with wedge matrix resection (WMR) and 55 with nail matrix phenolization (NMP). The patients were randomized on the basis of their address. All patients were reviewed by questionnaire 4 weeks postoperatively to establish the degree of pain, time of pain relief, walking and working ability, and the presence of infection. Furthermore, they were examined clinically at a median follow-up time of 11 months postoperatively to evaluate recurrence rate, rate of spicula formation, and patient satisfaction with regard to cosmesis and symptom relief. The data were tested for statistical significance using the chi-square test and Mann-Whitney rank sum test. The recurrence rate of ingrown toenail for the WMR group was 5.5% (3 patients) with a spicula rate of 36% (20 patients) and a reoperation rate of 20% (9 patients). In the NMP group, there were no recurrences (p = n.s.), the spicula rate was 7.3% (4 patients) (p < .005) and no patients were reoperated on (p < .016). Patient satisfaction with less pain and earlier pain relief was greatest in the NMP group. These results indicate that nail matrix phenolization is an efficient therapy for ingrown toenails and may be preferable to nail wedge resection.
authors.affiliation: Department of Orthopaedics. Esbjerg County Hospital, Denmark. Herold@dadlnet.dk
authors.forename: N
authors.initials: N
authors.lastname: Herold
authors.forename: S
authors.initials: S
authors.lastname: Houshian
authors.forename: P
authors.initials: P
authors.lastname: Riegels-Nielsen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016009:Chi-Square Distribution; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D009262:Nails / Q000601:surgery*; D009263:Nails, Ingrown / Q000601:surgery / Q000628:therapy*; D019800:Phenol / Q000627:therapeutic use*; D011446:Prospective Studies; D012597:Sclerosing Solutions / Q000627:therapeutic use*; D018709:Statistics, Nonparametric
chemical_list: D012597:Sclerosing Solutions; D019800:Phenol